Mercado Global de Tratamento da Toxoplasmose – Tendências da Indústria e Previsão para 2028

Análise de mercado e insights: Mercado global de tratamento da toxoplasmose

Espera-se que o mercado global de tratamento da toxoplasmose ganhe crescimento de mercado no período de previsão de 2021 a 2028. A Data Bridge Market Research analisa que o mercado está a crescer a um CAGR de 5,10% no período de previsão de investigação acima mencionado. Os mercados emergentes e os enormes investimentos em investigação e desenvolvimento são os fatores responsáveis ​​pelo crescimento deste mercado.

Além disso, o avanço tecnológico no tratamento e diagnóstico, o aumento da prevalência de doenças de origem alimentar e o aumento da incidência de infeções parasitárias em todo o mundo também impulsionam o crescimento do mercado. O aumento contínuo dos programas de sensibilização governamental e o aumento contínuo do ambiente anti-higiénico em países populosos de todo o mundo também impulsionam o crescimento do mercado. O aumento de novas opções de tratamento funciona como uma oportunidade para o crescimento do mercado. Mas, os efeitos secundários relacionados com os medicamentos antialérgicos , a falta de sensibilização nos países em desenvolvimento e a presença de tratamentos alternativos podem prejudicar o mercado global de tratamento da toxoplasmose.

Infeção por toxoplasmose causada pelo parasita unicelular conhecido por Toxoplasma gondii. A infeção ocorre geralmente pela ingestão de carne contaminada mal cozinhada, transmissão de mãe para filho durante a gravidez e exposição a fezes de gatos infetados. A infeção por toxoplasmose pode causar sintomas semelhantes aos da gripe em algumas pessoas, embora a maioria da população infetada nunca apresente qualquer tipo de sintomas. Outros sintomas menores são dor de cabeça, febre , fadiga, gânglios linfáticos inchados, dores no corpo e outros. Além disso, as pessoas que têm o sistema imunitário enfraquecido, como os doentes com VIH sob quimioterapia, podem desenvolver sinais e sintomas de infecção mais graves, como confusão, dores de cabeça, má coordenação, problemas pulmonares que podem assemelhar-se à tuberculose e outros.

Toxoplasmosis parasite is the most common and found across the world. According to the Centre of Disease Control (CDC) more than 40 million men, women, and children in the U.S. carry the Toxoplasma parasite. In the U.S. it is estimated that 11% of population with the age of 6 and older have been infected with Toxoplasma.

Moreover according to the European Centre for Disease Prevention and Control (ECDC) in 2017, approximately 194 cases reported with Toxoplasmosis infection in 22 countries. France accounted highest cases with 79% share. The number of notifications per 100 000 living new-borns was 5.3 in the EU/EEA, with the highest rate in France (19.9), followed by Slovenia, Poland and Bulgaria.

This toxoplasmosis treatment market provides details of market share, new developments and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions and technological innovations in the market. To understand the analysis and the market scenario contact us for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.

Global Toxoplasmosis treatment Market Scope and Market Size

Toxoplasmosis treatment market is segmented on the basis of type, treatment, population, end-users and distribution channel. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

• On the basis of type, the toxoplasmosis treatment market is segmented into acute toxoplasmosis, central nervous system (CNS) toxoplasmosis, congenital toxoplasmosis, ocular toxoplasmosis and others.
• On the basis of treatment, the toxoplasmosis treatment market is segmented into diagnosis, medication and others. Medication segment further divided into pyrimethamine/ clindamycin, sulfadiazine, folinic acid and others.
• On the basis of population, the toxoplasmosis treatment market is segmented into children and adults.
• On the basis of end-users, the toxoplasmosis treatment market is segmented into hospitals, specialty clinics and others.
• On the basis of distribution channel Toxoplasmosis treatment market has also been segmented into direct tender, hospital pharmacy, retail pharmacy, online pharmacy and others.

Toxoplasmosis treatment Market Country Level Analysis

Toxoplasmosis treatment market is analysed and market size information is provided by country, type, treatment, population, end-users and distribution channel as referenced above.

The countries covered in the toxoplasmosis treatment market report are U.S., Canada, Mexico in North America, Brazil, Argentina, Peru, Rest of South America, as part of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa, as a part of Middle East and Africa.

On geographical estimation, North America accounts the largest market share due to the presence of high healthcare expenditure and increased clinical studies for the treatment. Asia-Pacific is expected to account for the largest market share over coming years for the Toxoplasmosis treatment market due to constant rise in the incidence of toxoplasmosis infection and rising demand for cost-efficient therapeutics.

The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Patient Epidemiology Analysis

Toxoplasmosis treatment market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

Competitive Landscape and Toxoplasmosis Treatment Market Share Analysis

Toxoplasmosis treatment market competitive landscape provides details by competitor. details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to toxoplasmosis treatment market.

Os principais players abrangidos no mercado de tratamento da toxoplasmose são a Pfizer Inc., Mylan NV, Macleods Pharmaceuticals, Cadila Pharmaceuticals, Johnson & Johnson Services, Inc. Teva Pharmaceutical Industries Ltd., Bayer AG, Sun Pharmaceutical Industries Ltd., Perrigo Pharmaceutical plc. , Sandoz AG, Hikma Pharmaceutical PLC, Akron Inc., entre outros players nacionais e globais. Os analistas DBMR compreendem os pontos fortes competitivos e fornecem análises competitivas para cada concorrente em separado.

SKU-59659